NO323460B1 - Fremgangsmate til fremstilling i stor skala av en lagringsstabil trombinsammensetning med terapeutisk kvalitet som hovedsakelig er fri for virus - Google Patents

Fremgangsmate til fremstilling i stor skala av en lagringsstabil trombinsammensetning med terapeutisk kvalitet som hovedsakelig er fri for virus Download PDF

Info

Publication number: NO323460B1
Authority: NO; Norway
Prior art keywords: thrombin; approx; solution; stated; human
Prior art date: 1994-09-21

Application number

NO19971104A

Other languages

English (en)

Norwegian (no)

Other versions

NO971104D0 (no

NO971104L (no

Inventor

Trung Bui-Khac

Zbigniew Proba

Nicolas Dupuis

Teresa Brodniewics

Original Assignee

Haemacure Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-21

Filing date

1997-03-11

Publication date

2007-05-14

1997-03-11 Application filed by Haemacure Corp filed Critical Haemacure Corp

1997-03-11 Publication of NO971104D0 publication Critical patent/NO971104D0/no

1997-04-24 Publication of NO971104L publication Critical patent/NO971104L/no

2007-05-14 Publication of NO323460B1 publication Critical patent/NO323460B1/no

Links

108090000190 Thrombin Proteins 0.000 title claims abstract description 158
229960004072 thrombin Drugs 0.000 title claims abstract description 158
238000000034 method Methods 0.000 title claims abstract description 42
230000001225 therapeutic effect Effects 0.000 title claims abstract description 10
241000700605 Viruses Species 0.000 title claims description 30
239000000203 mixture Substances 0.000 title claims description 29
238000002360 preparation method Methods 0.000 title description 14
230000000694 effects Effects 0.000 claims abstract description 29
239000012537 formulation buffer Substances 0.000 claims abstract description 23
238000010438 heat treatment Methods 0.000 claims abstract description 11
230000000087 stabilizing effect Effects 0.000 claims abstract description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 5
239000002131 composite material Substances 0.000 claims abstract description 5
150000004676 glycans Chemical class 0.000 claims abstract description 5
238000011031 large-scale manufacturing process Methods 0.000 claims abstract description 5
229920001282 polysaccharide Polymers 0.000 claims abstract description 5
239000005017 polysaccharide Substances 0.000 claims abstract description 5
238000004255 ion exchange chromatography Methods 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 61
102000004169 proteins and genes Human genes 0.000 claims description 32
108090000623 proteins and genes Proteins 0.000 claims description 32
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 31
239000000047 product Substances 0.000 claims description 28
239000000872 buffer Substances 0.000 claims description 27
241000283690 Bos taurus Species 0.000 claims description 23
238000004587 chromatography analysis Methods 0.000 claims description 19
229960003766 thrombin (human) Drugs 0.000 claims description 19
210000002845 virion Anatomy 0.000 claims description 17
150000002632 lipids Chemical class 0.000 claims description 16
239000011780 sodium chloride Substances 0.000 claims description 15
239000000463 material Substances 0.000 claims description 13
239000012528 membrane Substances 0.000 claims description 10
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 9
108010071390 Serum Albumin Proteins 0.000 claims description 9
102000007562 Serum Albumin Human genes 0.000 claims description 9
239000007864 aqueous solution Substances 0.000 claims description 9
108010094028 Prothrombin Proteins 0.000 claims description 8
102100027378 Prothrombin Human genes 0.000 claims description 8
238000005341 cation exchange Methods 0.000 claims description 8
229940039716 prothrombin Drugs 0.000 claims description 8
239000012266 salt solution Substances 0.000 claims description 8
108091006905 Human Serum Albumin Proteins 0.000 claims description 7
102000008100 Human Serum Albumin Human genes 0.000 claims description 7
239000001509 sodium citrate Substances 0.000 claims description 6
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
239000006228 supernatant Substances 0.000 claims description 6
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
239000007853 buffer solution Substances 0.000 claims description 5
238000001914 filtration Methods 0.000 claims description 5
230000000415 inactivating effect Effects 0.000 claims description 5
229940098773 bovine serum albumin Drugs 0.000 claims description 3
239000001913 cellulose Substances 0.000 claims description 3
229920002678 cellulose Polymers 0.000 claims description 3
239000012510 hollow fiber Substances 0.000 claims description 3
239000012062 aqueous buffer Substances 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical group CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
239000007836 KH2PO4 Substances 0.000 claims 1
150000001860 citric acid derivatives Chemical class 0.000 claims 1
239000003480 eluent Substances 0.000 claims 1
229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
235000019796 monopotassium phosphate Nutrition 0.000 claims 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
238000000746 purification Methods 0.000 abstract description 24
230000002779 inactivation Effects 0.000 abstract description 7
230000003612 virological effect Effects 0.000 abstract description 7
239000008363 phosphate buffer Substances 0.000 abstract description 6
238000010828 elution Methods 0.000 abstract description 3
238000005342 ion exchange Methods 0.000 abstract description 3
238000011084 recovery Methods 0.000 abstract description 3
239000012467 final product Substances 0.000 abstract description 2
238000011100 viral filtration Methods 0.000 abstract description 2
210000002381 plasma Anatomy 0.000 description 25
239000007858 starting material Substances 0.000 description 13
102000009027 Albumins Human genes 0.000 description 12
108010088751 Albumins Proteins 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 11
238000011026 diafiltration Methods 0.000 description 10
239000004094 surface-active agent Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 7
238000003860 storage Methods 0.000 description 7
229910019142 PO4 Inorganic materials 0.000 description 6
239000010452 phosphate Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000001179 sorption measurement Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000000840 anti-viral effect Effects 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
102000004506 Blood Proteins Human genes 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
239000000356 contaminant Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 4
230000003253 viricidal effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000011358 absorbing material Substances 0.000 description 3
238000013375 chromatographic separation Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000002510 pyrogen Substances 0.000 description 3
239000004627 regenerated cellulose Substances 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010054218 Factor VIII Proteins 0.000 description 2
102000001690 Factor VIII Human genes 0.000 description 2
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical compound [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000011097 chromatography purification Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
ZURAKLKIKYCUJU-UHFFFAOYSA-N copper;azane Chemical compound N.[Cu+2] ZURAKLKIKYCUJU-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
239000012982 microporous membrane Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
-1 sulfopropyl Chemical group 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920003043 Cellulose fiber Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
241000539679 Defiwi virus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013466 adhesive and sealant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002155 anti-virotic effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108010012557 prothrombin complex concentrates Proteins 0.000 description 1
229960005480 sodium caprylate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/815—Enzyme separation or purification by sorption

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

NO19971104A 1994-09-21 1997-03-11 Fremgangsmate til fremstilling i stor skala av en lagringsstabil trombinsammensetning med terapeutisk kvalitet som hovedsakelig er fri for virus NO323460B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/309,583 US5506127A (en)	1994-09-21	1994-09-21	Therapeutic grade thrombin produced by chromatography
PCT/CA1995/000541 WO1996009376A1 (en)	1994-09-21	1995-09-21	Therapeutic grade thrombin production and products

Publications (3)

Publication Number	Publication Date
NO971104D0 NO971104D0 (no)	1997-03-11
NO971104L NO971104L (no)	1997-04-24
NO323460B1 true NO323460B1 (no)	2007-05-14

Family

ID=23198815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19971104A NO323460B1 (no)	1994-09-21	1997-03-11	Fremgangsmate til fremstilling i stor skala av en lagringsstabil trombinsammensetning med terapeutisk kvalitet som hovedsakelig er fri for virus

Country Status (12)

Country	Link
US (1)	US5506127A (de)
EP (1)	EP0782616B1 (de)
JP (1)	JP3628703B2 (de)
AT (1)	ATE315641T1 (de)
AU (1)	AU711298B2 (de)
DE (1)	DE69534749T2 (de)
DK (1)	DK0782616T3 (de)
ES (1)	ES2258264T3 (de)
NO (1)	NO323460B1 (de)
PT (1)	PT782616E (de)
RU (1)	RU2144081C1 (de)
WO (1)	WO1996009376A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4137996A1 (de) *	1991-11-19	1993-05-27	Behringwerke Ag	Verfahren zur herstellung eines virussicheren thrombinkonzentrates
DK83092D0 (da) *	1992-06-24	1992-06-24	Unes As	Fremgangsmaade til udvinding af thrombin
US5795780A (en) *	1993-06-23	1998-08-18	Bristol-Myers Squibb Company	Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes
JPH07308190A (ja) *	1994-05-18	1995-11-28	Green Cross Corp:The	トロンビンの製造方法
FI952196A0 (fi) *	1995-05-08	1995-05-08	Suomen Punainen Risti Veripalv	Framstaellning av immunoglobulin
US5702715A (en) *	1995-10-27	1997-12-30	Drying Technology	Reinforced biological sealants
WO2000062828A1 (en) *	1996-04-30	2000-10-26	Medtronic, Inc.	Autologous fibrin sealant and method for making the same
US5981254A (en) *	1997-10-30	1999-11-09	Haemacure Corporation	Process for producing thrombin from plasma
US6274090B1 (en)	1998-08-05	2001-08-14	Thermogenesis Corp.	Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
US6391609B1 (en) *	1998-10-07	2002-05-21	Sigma-Aldrich Co.	Thromboplastin reagents and methods for preparing and using such reagents
US6472162B1 (en)	1999-06-04	2002-10-29	Thermogenesis Corp.	Method for preparing thrombin for use in a biological glue
DE60032001T2 (de) *	1999-09-27	2007-05-31	Sysmex Corp.	Verfahren zur stabilisierung von thrombin
DE10012732A1 (de) *	2000-03-18	2001-09-20	Aventis Behring Gmbh	Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
ES2214967B1 (es) *	2003-03-06	2005-06-16	Probitas Pharma, S.A	Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
ES2226587B1 (es) *	2004-10-22	2005-12-16	Probitas Pharma, S.A.	Composicion de trombina estable.
US20060270014A1 (en) *	2005-05-26	2006-11-30	Dan Pawlak	Thrombin purification
AU2007264735B2 (en) *	2006-06-26	2012-11-08	Omrix Biopharmaceuticals Inc.	Virus removal by nanofiltration
RU2457248C2 (ru) *	2010-06-09	2012-07-27	Общество с ограниченной ответственностью фирма "Технология-Стандарт"	Способ промышленного получения тромбина
BR112013008738B1 (pt) *	2010-10-11	2017-12-19	Abbvie Bahamas Ltd.	Method for purification of a protein
EP2793934B1 (de) *	2011-12-23	2017-08-23	Merz Pharma GmbH & Co. KGaA	Neuartiges verfahren zur herstellung von di-ketten-proteinen zur verwendung bei menschen
JP6713479B2 (ja) *	2015-02-25	2020-06-24	オムリックス・バイオファーマシューティカルズ・リミテッドＯｍｒｉｘＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ．	トロンビン及びその分解ポリペプチドの精製及び定量化方法
CA3091348A1 (en) *	2018-02-19	2019-08-22	Bayer Healthcare Llc	Modified filter membrane and method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4083957A (en) *	1974-07-26	1978-04-11	Lang John L	Process for the alteration of the sex-ratio of mammals
NL7602423A (nl) *	1976-03-08	1977-09-12	Leuven Res & Dev Vzw	Bepaling van heparine in bloedplasma.
US4380511A (en) *	1981-08-12	1983-04-19	Miles Laboratories, Inc.	Purification of bovine thrombin
US4540573A (en) *	1983-07-14	1985-09-10	New York Blood Center, Inc.	Undenatured virus-free biologically active protein derivatives
US4696812A (en) *	1985-10-28	1987-09-29	Warner-Lambert Company	Thrombin preparations
US4965203A (en) *	1987-01-28	1990-10-23	Warner-Lambert Company	Purified thrombin preparations
JPS63243032A (ja) *	1987-03-27	1988-10-07	Green Cross Corp:The	トロンビンの加熱処理方法
JPS6440433A (en) *	1987-08-05	1989-02-10	Green Cross Corp	Aqueous liquid composition of thrombin
SU1527261A1 (ru) *	1988-03-21	1989-12-07	Институт Химической И Биологической Физики Ан Эсср	Способ получени тромбина
JP2832835B2 (ja) *	1988-12-21	1998-12-09	旭化成工業株式会社	ウイルス除去方法
DE3843126C3 (de) *	1988-12-22	1994-10-06	Octapharma Ag	Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
EP0378208B2 (de) *	1989-01-13	2003-01-15	Mitsubishi Pharma Corporation	Verfahren zur Herstellung einer Protein enthaltenden Zusammensetzung
US5281528A (en) *	1989-12-18	1994-01-25	Warner-Lambert Company	Process for purified thromboplastin for ultra-pure thrombin preparation
IE73210B1 (en) *	1990-01-24	1997-05-07	Warner Lambert Co	Process for the production of thrombin and high purity thrombin preparation thereby obtained
ES2131504T3 (es) *	1990-02-20	1999-08-01	Baxter Int	Trombina humana purificada viricamente segura.
JPH0813750B2 (ja) *	1990-03-01	1996-02-14	持田製薬株式会社	経口用トロンビン製剤
JP3127232B2 (ja) *	1990-03-08	2001-01-22	ウェルファイド株式会社	蛋白質製剤の製造法
JP3093821B2 (ja) *	1991-06-19	2000-10-03	旭化成工業株式会社	銅アンモニア法再生セルロース多孔性中空糸膜の製造方法
FR2679251B1 (fr) *	1991-07-18	1993-11-12	Nord Assoc Essor Transfusion San	Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
AT398079B (de) *	1991-11-04	1994-09-26	Immuno Ag	Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
US5331092A (en) *	1992-11-06	1994-07-19	Coletica	Process of preparation of collagen containing in major proportion insoluble collagen and collagen having high mechanical resistance and thermal stability obtained thereby
US5229172A (en) *	1993-01-19	1993-07-20	Medtronic, Inc.	Modification of polymeric surface by graft polymerization
JP2003318980A (ja) *	2002-04-24	2003-11-07	Mitsubishi Electric Corp	ショートパケット用伝送フォーマット並びにゲートウェイシステム

1994
- 1994-09-21 US US08/309,583 patent/US5506127A/en not_active Expired - Lifetime
1995
- 1995-09-21 RU RU97106349A patent/RU2144081C1/ru not_active IP Right Cessation
- 1995-09-21 DE DE69534749T patent/DE69534749T2/de not_active Expired - Lifetime
- 1995-09-21 WO PCT/CA1995/000541 patent/WO1996009376A1/en not_active Ceased
- 1995-09-21 JP JP51048396A patent/JP3628703B2/ja not_active Expired - Fee Related
- 1995-09-21 AU AU35151/95A patent/AU711298B2/en not_active Ceased
- 1995-09-21 EP EP95931863A patent/EP0782616B1/de not_active Expired - Lifetime
- 1995-09-21 ES ES95931863T patent/ES2258264T3/es not_active Expired - Lifetime
- 1995-09-21 DK DK95931863T patent/DK0782616T3/da active
- 1995-09-21 PT PT95931863T patent/PT782616E/pt unknown
- 1995-09-21 AT AT95931863T patent/ATE315641T1/de not_active IP Right Cessation
1997
- 1997-03-11 NO NO19971104A patent/NO323460B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO971104D0 (no)	1997-03-11
EP0782616A1 (de)	1997-07-09
DK0782616T3 (da)	2006-05-22
AU711298B2 (en)	1999-10-07
JPH10505753A (ja)	1998-06-09
PT782616E (pt)	2006-05-31
AU3515195A (en)	1996-04-09
NO971104L (no)	1997-04-24
DE69534749T2 (de)	2006-11-02
ATE315641T1 (de)	2006-02-15
RU2144081C1 (ru)	2000-01-10
WO1996009376A1 (en)	1996-03-28
US5506127A (en)	1996-04-09
DE69534749D1 (de)	2006-04-06
ES2258264T3 (es)	2006-08-16
EP0782616B1 (de)	2006-01-11
JP3628703B2 (ja)	2005-03-16

Legal Events

Date	Code	Title	Description
2011-05-09	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
RU2144081C1 (ru)	2000-01-10	Способ крупномасштабного производства устойчивой при хранении композиции тромбина терапевтической степени чистоты
US4877866A (en)	1989-10-31	Method of producing a virus safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation
US5981254A (en)	1999-11-09	Process for producing thrombin from plasma
US4876241A (en)	1989-10-24	Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US4424206A (en)	1984-01-03	Process for heat treatment of aqueous solution containing cold insoluble globulin to inactivate hepatitis virus
US5639730A (en)	1997-06-17	Method of producing a virus-safe biological preparation
RU2000113224A (ru)	2002-05-20	Способ продуцирования в высокой степени вирусобезопасных компонентов для получения фибринового клея из пула плазмы человека
NO177188B (no)	1995-04-24	Fremgangsmåte for separering av humane eller animalske plasmaproteiner
US4749783A (en)	1988-06-07	Viral inactivation and purification of active proteins
RU97106349A (ru)	1999-05-10	Производство и продукты тромбина терапевтической степени чистоты
JP3471379B2 (ja)	2003-12-02	ヒトアンチトロンビン−ｉｉｉの調製方法
JPH06505494A (ja)	1994-06-23	Ｉｘ因子の調製
RU2006107533A (ru)	2006-07-27	Способ получения раствора альфа-1-антитрипсина
NO176234B (no)	1994-11-21	Fremgangsmåte for inaktivering av patogener i et biologisk eller et farmasöytisk materiale
US5907032A (en)	1999-05-25	Thrombin preparation
WO1998030230A1 (en)	1998-07-16	Protein-containing compositions and process for producing the same
CA2822229A1 (en)	2014-02-09	Caprylate viral deactivation
US5945103A (en)	1999-08-31	Process for producing thrombin
DK175644B1 (da)	2005-01-03	Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter
CA2228031A1 (en)	1997-02-13	Doubly virus-inactivated human blood plasma, blood plasma derivatives produced therefrom and method for their production
JPH0733799A (ja)	1995-02-03	高比活性トロンビンおよびその製造方法
JPH04365481A (ja)	1992-12-17	トロンビンの製造法